OP169 MONOCLONAL ANTIBODIES IN THE MANAGEMENT OF CHRONIC WOUNDS: A COMPREHENSIVE LITERATURE REVIEW.

Aim: Chronic wounds represent a clinical challenge of considerable complexity, given the articulated pathophysiology underlying their origin and the burden of long-term management with local dressings. Monoclonal antibodies (mAbs) are emerging as a novel therapeutic choice in clinical experiences of difficult to heal wounds, but no data are still available as a comprehensive view of their use in wound care. The goal of our work was then to review the use of those drugs in the existing literature. Method: We performed a comprehensive literature review of 167 articles examining clinical cases of chronic wounds treated with mAbs. Inflammatory pathologies with possible ulcerative outcomes, such as hidradenitis suppurativa, were excluded from the analysis. Results / Discussion: mAbs were found to be effective in treating wounds from 16 different etiopathogenesis. The most represented diseases were pyoderma gangrenosum treated with 12 different mAbs, necrobiosis lipoidica and cutaneous vasculitis treated with 3 different mAbs. The total number of different mAbs analyzed from the literature was 14. Rituximab was effective in 7/16 diseases (43.75%), followed by Tocilizumab used in 4/16 (25%) diseases and Etanercept and Adalimumab, both applied for 3/16 (18.75%) conditions. Conclusion: mAbs represent a therapeutic opportunity in cases of chronic wounds recalcitrant to standard treatments. Due to the complex molecular landscape of wound healing, it is not possible to identify a single target molecule and for this reason the use of mAbs should be interpreted as a translational application to limited cases of multi-resistant conditions. [ABSTRACT FROM AUTHOR]